ストックスクリーナーアプリを入手
36.32
0.33%
-0.12
Xenon Pharmaceuticals Inc (XENE) 最新ニュース
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD - Investing.com
Xenon Pharmaceuticals stock hits 52-week low at 36.06 USD By Investing.com - Investing.com Canada
XENE Assumed by Guggenheim -- Buy Rating Assigned with Price Tar - GuruFocus
Xenon Pharmaceuticals stock gets 28,350 awards for new hires - AD HOC NEWS
President of Xenon Pharmaceuticals Picks Up 88% More Stock - Simply Wall Street
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Eight new Xenon employees get options to buy shares at $38.93 - Stock Titan
Xenon Pharmaceuticals (XENE) Shares Rise After CEO and CFO Buy $1.7M in Stock - GuruFocus
Xenon rises on insider buys from CEO and CFO (XENE:NASDAQ) - Seeking Alpha
Xenon Pharmaceuticals (XENE) CFO Thomas Kelly Buys 15,000 Shares in Open-Market Purchase - GuruFocus
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says - Yahoo Finance
Xenon Pharmaceuticals Insider Bought Shares Worth $1,121,400, According to a Recent SEC Filing - Yahoo Finance
At $37.316 each, CFO Kelly buys 15,000 Xenon Pharmaceuticals (XENE) shares. - Stock Titan
At $37.38 a share, Xenon Pharmaceuticals (XENE) CEO Ian Mortimer buys company stock. - Stock Titan
Gross margin % of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.70 after FDA filing - AD HOC NEWS
Total common shares outstanding of Xenon Pharmaceuticals Inc. – HAN:XP0 - TradingView
Xenon Pharmaceuticals Inc. Balance Sheet – HAN:XP0 - TradingView
Xenon Pharmaceuticals stock trades at EUR 32.30 after trial pause - AD HOC NEWS
Xenon Pharmaceuticals Inc. (XENE) Interactive Stock ChartYahoo Finance - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. (XENE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc. (XENE) stock price, news, quote and history - Yahoo Finance Australia
XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law - Business Wire
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback? - Yahoo Finance
Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) - PR Newswire
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate (XENE) - Seeking Alpha
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors - GlobeNewswire
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit - GlobeNewswire
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment - Yahoo Finance
Xenon will present a drug being developed for epilepsy and two types of depression - Stock Titan
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data - Yahoo Finance
Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - benzinga.com
Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold From Buy, Adjusts PT to $46 From $90 - Yahoo Finance
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - Yahoo Finance
Xenon Pharmaceuticals falls 30% after depression trial enrollment pause - Yahoo Finance
Wedbush Cuts Price Target on Xenon Pharmaceuticals to $55 From $71, Keeps Outperform Rating - Yahoo Finance
Xenon Stock Craters 30% on Drug Trial Setback. Its Failure Could Be This Biotech’s Gain. - Barron's
Xenon Announces Azetukalner NDA Submission to FDA for Focal - GlobeNewswire
Xenon Pharmaceuticals: Epilepsy Got It To $59; Depression Has To Take It From Here - Seeking Alpha
Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care - Yahoo Finance
A drugmaker plans a 30-minute healthcare talk in Boston Sept. 9. Xenon will present. - Stock Titan
Xenon to Present at Wells Fargo Healthcare Conference - Yahoo Finance
Behavioral Patterns of XENE and Institutional Flows - Stock Traders Daily
Xenon Pharmaceuticals stock holds firm as analysts stick to buy ratings - ad-hoc-news.de
Xenon Pharmaceuticals (XENE) CMO sells 7,068 shares in Rule 10b5-1 plan trades around $61. - Stock Titan
Xenon Pharma (NASDAQ: XENE) holder to sell 7,068 shares - Stock Titan
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders - Yahoo Finance
0.17%
0.60%
大文字化:
|
ボリューム (24 時間):